What is the long-term trend for CONMED's contingent consideration fair value adjustments?

Over 3 years (2022 to 2025), CONMED's contingent consideration fair value adjustments has grown at a 108.9% compound annual growth rate (CAGR), from $2.52M to $22.95M.

CONMED CNMD Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Boston ScientificBSX

-$30M-700%

IAR

Integra LifeSciencesIART

——

Merit Medical SystemsMMSI

——

EnovisENOV

——

Globus MedicalGMED

——

TFX

TeleflexTFX

——

Other financials

Income statement

See full

Revenue$317.0M-1.3%

Gross profit$183.4M+3.2%

Operating income$25.4M+59.3%

Net income$13.8M+129%

EPS (diluted)$0.45+137%

Balance sheet

See full

Cash & equivalents$35.0M-1.3%

Total debt$862.6M-3.6%

Total equity$1.0B+4.1%

Total assets$2.3B+0.8%

Cash flow

See full

Operating cash flow$13.5M-67.6%

CapEx$2.9M-23.5%

Free cash flow$10.6M-72.0%

Valuation

See full

Market cap$1.07B-34.0%

Enterprise value$1.89B-23.5%

P/E19.4×+5.8×

P/S0.8×-0.5×

Profitability

See full

Gross margin55.2%-1.0pp

Operating margin8.2%-5.6pp

Net margin4%-5.0pp

FCF margin9%-3.5pp

Returns & leverage

See full

Return on equity5.5%-7.5pp

Debt / equity0.8×-0.1×

Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CONMED's contingent consideration fair value adjustments?: CONMED (CNMD) reported contingent consideration fair value adjustments of $722K in Q1 2026.
How has CONMED's contingent consideration fair value adjustments changed year-over-year?: CONMED's contingent consideration fair value adjustments decreased by 81.8% year-over-year, from $3.96M to $722K.
What is the long-term trend for CONMED's contingent consideration fair value adjustments?: Over 3 years (2022 to 2025), CONMED's contingent consideration fair value adjustments has grown at a 108.9% compound annual growth rate (CAGR), from $2.52M to $22.95M.